151751-Najiba-Chargi

252 CHAPTER 13 15. Marty E, Liu Y, Samuel A, Or O, Lane J. A review of sarcopenia: Enhancing aware- ness of an increasingly prevalent disease. Bone . 2017;105:276-286. doi:10.1016/j. bone.2017.09.008 16. Tan BHL, Brammer K, Randhawa N, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant che- motherapy for oesophago-gastric cancer. Eur J Surg Oncol . 2015;41(3):333-338. doi:10.1016/j.ejso.2014.11.040 17. Ali R, Baracos VE, Sawyer MB, et al. Lean body mass as an independent determi- nant of dose-limiting toxicity and neurop- athy in patients with colon cancer treat- ed with FOLFOX regimens. Cancer Med . 2016;5(4):607-616. doi:10.1002/cam4.621 18. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med . 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097 19. Hayden JA, van der Windt DA, Cart - wright JL, Côté P, Bombardier C. Assess - ing bias in studies of prognostic factors. Ann Intern Med . 2013;158(4):280-286. doi:10.7326/0003-4819-158-4-201302190- 00009 20. da Rocha IMG, Marcadenti A, de Medeiros GOC, et al. Is cachexia associated with che - motherapy toxicities in gastrointestinal cancer patients? A prospective study. J Ca- chexia Sarcopenia Muscle . 2019;10(2):445- 454. doi:10.1002/jcsm.12391 21. Daly LE, Power DG, O’Reilly Á, et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer . 2017;116(3):310-317. doi:10.1038/ bjc.2016.431 22. Dijksterhuis WPM, Pruijt MJ, van der Woude SO, et al. Association between body com - position, survival, and toxicity in advanced esophagogastric cancer patients receiv- ing palliative chemotherapy. J Cachexia Sarcopenia Muscle . 2019;10(1):199-206. doi:10.1002/jcsm.12371 23. Freckelton J, Croagh D, Holt DQ, et al. Body Composition Adjusted Dosing of Gemcit - abine-Nab-Paclitaxel in Pancreatic Cancer Does Not Predict Toxicity Compared to Body Surface Area Dosing. Nutr Cancer . 2019;71(4):624-628. doi:10.1080/01635581 .2018.1542011 24. Ganju RG, Morse R, Hoover A, TenNapel M, Lominska CE. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. Radiother Oncol . 2019;137:117-124. doi:10.1016/j. radonc.2019.04.023 25. Huiskamp LFJ, Chargi N, Devriese LA, de Jong PA, de Bree R. The predictive and prog - nostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concom- itant cetuximab and radiotherapy. Eur Arch Oto-Rhino-Laryngology . 2020;277(10):2847- 2858. doi:10.1007/s00405-020-05972-2 26. Kobayashi H, Okuma T, Oka H, et al. Body composition as a predictor of toxicity after treatment with eribulin for advanced soft tissue sarcoma. Int J Clin Oncol . 2019;24(4):437-444. doi:10.1007/s10147- 018-1370-8 27. Kurk S, Peeters P, Stellato R, et al. Skel - etal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle . 2019;10(4):803-813. doi:10.1002/jcsm.12436 28. Looijaard SMLM, Meskers CGM, Slee ‐ Valenti- jn MS, et al. Computed Tomography ‐ Based Body Composition Is Not Consistently Asso- ciated with Outcome in Older Patients with Colorectal Cancer. Oncologist . 2020;25(3). doi:10.1634/theoncologist.2019-0590